132 related articles for article (PubMed ID: 38154386)
21. Targeting ovarian tumor cell adhesion mediated by tissue transglutaminase.
Khanna M; Chelladurai B; Gavini A; Li L; Shao M; Courtney D; Turchi JJ; Matei D; Meroueh S
Mol Cancer Ther; 2011 Apr; 10(4):626-36. PubMed ID: 21330459
[TBL] [Abstract][Full Text] [Related]
22. Transglutaminase 2 has higher affinity for relaxed than for stretched fibronectin fibers.
Selcuk K; Leitner A; Braun L; Le Blanc F; Pacak P; Pot S; Vogel V
Matrix Biol; 2024 Jan; 125():113-132. PubMed ID: 38135164
[TBL] [Abstract][Full Text] [Related]
23. Screening and Development of Transglutaminase-2 Inhibitors and their Derivative as Anti-lung Cancer Agent by in silico and in vitro Approaches.
Parvatikar PP; Patil S; Hoskeri J; Swargam S; Kulkarni RV; Das KK
Curr Comput Aided Drug Des; 2022; 18(1):41-51. PubMed ID: 34225635
[TBL] [Abstract][Full Text] [Related]
24. Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation.
Sakai I; Miyake H; Fujisawa M
BJU Int; 2013 Jul; 112(2):E211-20. PubMed ID: 23305097
[TBL] [Abstract][Full Text] [Related]
25. The increased transglutaminase 2 expression levels during initial tumorigenesis predict increased risk of metastasis and decreased disease-free and cancer-specific survivals in renal cell carcinoma.
Erdem S; Yegen G; Telci D; Yildiz I; Tefik T; Issever H; Kilicaslan I; Sanli O
World J Urol; 2015 Oct; 33(10):1553-60. PubMed ID: 25515319
[TBL] [Abstract][Full Text] [Related]
26. Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma.
Vatsyayan R; Singhal J; Nagaprashantha LD; Awasthi S; Singhal SS
Mol Carcinog; 2013 Jan; 52(1):39-48. PubMed ID: 22006587
[TBL] [Abstract][Full Text] [Related]
27. TG2 protects neuroblastoma cells against DNA-damage-induced stress, suppresses p53 activation.
Tucholski J
Amino Acids; 2010 Jul; 39(2):523-32. PubMed ID: 20112034
[TBL] [Abstract][Full Text] [Related]
28. Action of YM155 on clear cell renal cell carcinoma does not depend on survivin expression levels.
Sim MY; Huynh H; Go ML; Yuen JSP
PLoS One; 2017; 12(6):e0178168. PubMed ID: 28582447
[TBL] [Abstract][Full Text] [Related]
29. Pyrrolidine dithiocarbamate exerts anti-proliferative and pro-apoptotic effects in renal cell carcinoma cell lines.
Morais C; Pat B; Gobe G; Johnson DW; Healy H
Nephrol Dial Transplant; 2006 Dec; 21(12):3377-88. PubMed ID: 16998220
[TBL] [Abstract][Full Text] [Related]
30. Apigenin inhibits renal cell carcinoma cell proliferation.
Meng S; Zhu Y; Li JF; Wang X; Liang Z; Li SQ; Xu X; Chen H; Liu B; Zheng XY; Xie LP
Oncotarget; 2017 Mar; 8(12):19834-19842. PubMed ID: 28423637
[TBL] [Abstract][Full Text] [Related]
31. Inhibitors of tissue transglutaminase.
Keillor JW; Apperley KY; Akbar A
Trends Pharmacol Sci; 2015 Jan; 36(1):32-40. PubMed ID: 25500711
[TBL] [Abstract][Full Text] [Related]
32. Mechanism of gypenosides of Gynostemma pentaphyllum inducing apoptosis of renal cell carcinoma by PI3K/AKT/mTOR pathway.
Liu H; Li X; Duan Y; Xie JB; Piao XL
J Ethnopharmacol; 2021 May; 271():113907. PubMed ID: 33556477
[TBL] [Abstract][Full Text] [Related]
33. A novel Apigenin derivative suppresses renal cell carcinoma via directly inhibiting wild-type and mutant MET.
Li J; Tan G; Cai Y; Liu R; Xiong X; Gu B; He W; Liu B; Ren Q; Wu J; Chi B; Zhang H; Zhao Y; Xu Y; Zou Z; Kang F; Xu K
Biochem Pharmacol; 2021 Aug; 190():114620. PubMed ID: 34043966
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of Transglutaminase 2 as a Therapeutic Strategy in Celiac Disease-In Vitro Studies in Intestinal Cells and Duodenal Biopsies.
Stricker S; de Laffolie J; Zimmer KP; Rudloff S
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902226
[TBL] [Abstract][Full Text] [Related]
35. VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma.
Razafinjatovo CF; Stiehl D; Deininger E; Rechsteiner M; Moch H; Schraml P
Oncotarget; 2017 Feb; 8(6):10199-10212. PubMed ID: 28052007
[TBL] [Abstract][Full Text] [Related]
36. Enhancement of Fas-mediated apoptosis in renal cell carcinoma cells by adriamycin.
Wu XX; Mizutani Y; Kakehi Y; Yoshida O; Ogawa O
Cancer Res; 2000 Jun; 60(11):2912-8. PubMed ID: 10850437
[TBL] [Abstract][Full Text] [Related]
37. Root extract of Hemsleya amabilis Diels suppresses renal cell carcinoma cell growth through inducing apoptosis and G
Li K; You G; Jiang K; Wang R; Li W; Meng Y; Fang Y; Chen W; Zhu G; Song J; Wang W; Su H; Hu B; Sun F; Jia Z; Li C; Zhu J
J Ethnopharmacol; 2024 Jan; 318(Pt B):117014. PubMed ID: 37557938
[TBL] [Abstract][Full Text] [Related]
38. Development of carbon-11 labeled acryl amides for selective PET imaging of active tissue transglutaminase.
van der Wildt B; Wilhelmus MM; Bijkerk J; Haveman LY; Kooijman EJ; Schuit RC; Bol JG; Jongenelen CA; Lammertsma AA; Drukarch B; Windhorst AD
Nucl Med Biol; 2016 Apr; 43(4):232-42. PubMed ID: 27067043
[TBL] [Abstract][Full Text] [Related]
39. Recent developments in small molecule therapies for renal cell carcinoma.
Song M
Eur J Med Chem; 2017 Dec; 142():383-392. PubMed ID: 28844802
[TBL] [Abstract][Full Text] [Related]
40. Acylideneoxoindoles: a new class of reversible inhibitors of human transglutaminase 2.
Klöck C; Jin X; Choi K; Khosla C; Madrid PB; Spencer A; Raimundo BC; Boardman P; Lanza G; Griffin JH
Bioorg Med Chem Lett; 2011 May; 21(9):2692-6. PubMed ID: 21215619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
